Publications
Detailed Information
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, Koung Jin | - |
dc.contributor.author | Kim, Se Hyun | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.date.accessioned | 2020-04-27T11:05:33Z | - |
dc.date.available | 2020-04-27T11:05:33Z | - |
dc.date.created | 2019-05-29 | - |
dc.date.issued | 2018-03 | - |
dc.identifier.citation | Cancer Immunology, Immunotherapy, Vol.67 No.3, pp.459-470 | - |
dc.identifier.issn | 0340-7004 | - |
dc.identifier.other | 74445 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165244 | - |
dc.description.abstract | We investigated inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) that may predict the response to anti-PD-1 (programmed cell death protein 1) antibody therapy. Data from 54 patients with non-small cell lung cancer (NSCLC) treated with anti-PD-1 antibodies were retrospectively analyzed. The NLR was assessed at baseline and 6 weeks after the start of treatment (post-treatment). Eighteen of 54 patients (33.3%) had objective responses to treatment. Older age, absence of brain metastasis, low post-treatment NLR (< 5), and immune-related adverse events were significantly associated with response. Patients with a high post-treatment NLR (< 5) had significantly shorter progression-free survival (PFS) than those with a low post-treatment NLR (median, 1.3 vs. 6.1 months, p < 0.001). Multivariate analysis demonstrated that high post-treatment NLR [hazard ratio (HR) 15.1, 95% confidence interval (CI) 1.5-50.1, p < 0.001], liver metastasis (HR 4.9, 95% CI 1.9-12.4, p = 0.001), and brain metastasis (HR 3.2, 95% CI 1.3-8.2, p = 0.013) were independent prognostic factors of shorter PFS. Overall survival (OS) was significantly different in patients with high and low post-treatment NLRs (median, 2.1 vs. 14.0 months, p < 0.001). A high post-treatment NLR remained an independent prognostic factor for OS in multivariate analysis (HR 3.9, 95% CI 1.6-9.2, p = 0.003). The NLR at 6 weeks after treatment initiation was a prognostic marker in patients with advanced NSCLC treated with anti-PD-1 antibody. Further studies are warranted to evaluate the role of the 6-week NLR as a predictor in anti-PD-1 antibody treatment. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 이종석 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.identifier.doi | 10.1007/s00262-017-2092-x | - |
dc.citation.journaltitle | Cancer Immunology, Immunotherapy | - |
dc.identifier.wosid | 000426060600011 | - |
dc.identifier.scopusid | 2-s2.0-85036506239 | - |
dc.citation.endpage | 470 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 459 | - |
dc.citation.volume | 67 | - |
dc.identifier.sci | 000426060600011 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | METASTATIC MELANOMA PATIENTS | - |
dc.subject.keywordPlus | PRETREATMENT NEUTROPHIL | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | PREDICTS PROGNOSIS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | IPILIMUMAB | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordAuthor | Neutrophil-to-lymphocyte ratio | - |
dc.subject.keywordAuthor | Anti-PD-1 antibody | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Prognostic value | - |
dc.subject.keywordAuthor | Prognosis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.